Nobivac^® Lepto₄

Biological name

Leptospira canicola, gryppotyphosa, icterohaemorrhagiae, pomona Bacterin

The only canine leptospirosis vaccine specifically proven to protect against mortality and urinary shedding.

Features and benefits

• Prevented mortality caused by 4 virulent Leptospira serovars¹
• Clinical efficacy results showed that Nobivac Lepto₄ prevented liver dysfunction and thrombocytopenia¹
• The only vaccine proven to protect against mortality and leptospiruria
• Significantly reduced leptospiremia¹
• Proven safe and well tolerated in multiple studies¹
• Available in 2 convenient forms

Indication

• Indicated as an aid in the prevention of disease and mortality
• Prevents leptospiruria associated with:
  • L. grippotyphosa
  • L. canicola
  • L. icterohaemorrhagiae
• Aids in the prevention of leptospiruria associated with:
  • L. pomona
• Recommended for use in healthy dogs 8 weeks of age or older

Safety information

• Safety confirmed in a 749-dog field study¹
• Well tolerated on subcutaneous administration
• Proven safe across a variety of breeds and ages¹
• Now featuring an even higher level of quality due to new VacciPure™ filtration

Dosage and administration

• Subcutaneous injection
• Two 1-mL doses given 2 to 4 weeks apart
• Last dose may be given at 12 weeks of age
• Annual revaccination with 1 dose is recommended
• Available in a 25 x 1-mL dose

For further information, including complete directions and warnings, please see the product label

Product label(s) and MSDS

Reference:

1. Data on file, Merck Animal Health.